Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 10/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18358125 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDNPSR1ENPP1 | |
| SCHEMBL31728547 | 0.79 | PDE2A (0.40) | PDE2APDE3AALDH1A1KDM4EHPGD | |
| SCHEMBL9680379 | 0.76 | KDM4E (0.46) | ALDH1A1KDM4EHPGDPDE10ANPSR1 | |
| SCHEMBL864946 | 0.73 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDNPSR1ENPP1 | |
| SCHEMBL18358397 | 0.72 | ALDH1A1 (0.48) | PDE2APDE3AALDH1A1KDM4EHPGD | |
| SCHEMBL18372890 | 0.70 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDENPP1MBOAT4 | |
| SCHEMBL31465470 | 0.69 | PDE10A (0.61) | PDE2APDE3BPDE10A | |
| SCHEMBL10909304 | 0.69 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDNPSR1ENPP1 | |
| SCHEMBL31465349 | 0.69 | CDK2 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL7433052 | 0.69 | KDM1A (0.44) | ALDH1A1KDM4EHPGDNPSR1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233865-A1 | ENPP1 INHIBITORS | RE VENTURES I, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-109923116-B | [1,2,4] triazolo [1,5-a ] pyrimidine derivatives as PDE2 inhibitors | 詹森药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-109890824-B | [1,2,4] triazolo [1,5-a ] pyrimidine compounds as PDE2 inhibitors | 詹森药业有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3535268-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-09 | — | — | EP | disclosed |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2021-03-16 | — | — | US | disclosed |
| EP-3535267-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-30 | — | — | EP | disclosed |
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | US | disclosed |
| EP-3535267-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PDE2 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-09-11 | — | — | EP | disclosed |
| EP-3535268-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-09-11 | — | — | EP | disclosed |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2017000277-A1 | SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017003894-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055858-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE3A 5/4885ALDH1A1 391/4885 |
| US-20190276462-A1 | [1,2,4]TRIAZOLO[1,5‐A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE3A 7/4885ALDH1A1 404/4885 |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE3A, PDE4D | PDE2A 1/4885PDE3A 2/4885ALDH1A1 1376/4885 |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | PDE2A, PDE3A, PDE4D | PDE2A 1/4885PDE3A 2/4885ALDH1A1 1376/4885 |
| US-11319321-B2 | [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE3A 5/4885ALDH1A1 391/4885 |
| US-10947242-B2 | [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE3A 5/4885ALDH1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.